1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22649
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDrosos, A. A.en
dc.contributor.authorVoulgari, P. V.en
dc.contributor.authorPapadopoulos, I. A.en
dc.contributor.authorPoliti, E. N.en
dc.contributor.authorGeorgiou, P. E.en
dc.contributor.authorZikou, A. K.en
dc.date.accessioned2015-11-24T19:25:42Z-
dc.date.available2015-11-24T19:25:42Z-
dc.identifier.issn0392-856X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22649-
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntirheumatic Agents/*therapeutic useen
dc.subjectArthritis, Rheumatoid/blood/*drug therapy/physiopathologyen
dc.subjectBlood Sedimentation/drug effectsen
dc.subjectC-Reactive Protein/metabolismen
dc.subjectCyclosporine/*therapeutic useen
dc.subjectDrug Therapy, Combinationen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMethotrexate/therapeutic useen
dc.subjectMiddle Ageden
dc.subjectPrednisolone/therapeutic useen
dc.subjectProspective Studiesen
dc.subjectSafetyen
dc.subjectSeverity of Illness Indexen
dc.subjectTreatment Outcomeen
dc.titleCyclosporine A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9844762-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1998-
heal.abstractOBJECTIVE: To investigate the efficacy, tolerability and safety of cyclosporine A (CSA) in early rheumatoid arthritis (RA) patients. METHODS: Patients with an early diagnosis of RA, a disease duration of less than 3 years, and without prior disease modifying antirheumatic drug (DMARD) treatment were studied. They randomly received oral CSA (3 mg/kg/day) or oral methotrexate (MTX) (0.15 mg/kg/week). In addition, all patients in both groups received oral prednisone (7.5 mg/day). RESULTS: Fifty-two patients were assigned to the CSA group and 51 to the MTX group. After 24 months of treatment, 48 patients from the CSA group and 48 from the MTX group showed significant clinical improvement. This was evaluated by the duration of morning stiffness, grip strength, the total joint count, joint swelling, and joint tenderness and pain, compared to pre-treatment values. The clinical improvement was also associated with a significant decrease in ESR and CRP values in both groups. No significant radiological deterioration was observed in the CSA patients compared to those treated with MTX after 24 months. Four patients from the CSA group dropped out of the study, two because of a synovitis flare, one because of severe hypertrichosis and one because of severe gingival hyperplasia. Three patients from the MTX group withdrew, one because of disease flare-up and two because of gastrointestinal disturbances. CONCLUSION: Early immunointervention in RA patients appears to be crucial to limit the development of joint damage. Cyclosporine A appears to be effective, well tolerated and safe in the long-term treatment of RA and can therefore be used as a first immunomodulatory drug in the armamentarium for the treatment of RA.en
heal.journalNameClin Exp Rheumatolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons